2024
The association between aberrant salience and psychotic experiences in general population twins, and genetic vulnerability as a modifier
Drukker M, Todor T, Bongaarts J, Broggi E, Kelkar M, Wigglesworth T, Verhiel K, van Leeuwen K, Koster M, Derom C, Thiery E, De Hert M, Menne-Lothmann C, Decoster J, Collip D, van Winkel R, Jacobs N, Guloksuz S, Rutten B, van Os J. The association between aberrant salience and psychotic experiences in general population twins, and genetic vulnerability as a modifier. BMC Psychiatry 2024, 24: 736. PMID: 39462331, PMCID: PMC11515186, DOI: 10.1186/s12888-024-06176-2.Peer-Reviewed Original ResearchConceptsAberrant salienceGeneral population twinsPsychotic experiencesGenetic vulnerabilityGeneral population samplePsychotic symptomsAssociated with psychotic experiencesUltra-high-risk patientsPositive symptom scalesSubclinical psychotic symptomsWhite noise taskEpisode psychosis patientsAssociated with psychosisPopulation samplePsychosis spectrumPsychosis patientsSymptom ScaleNoise taskSaliencePsychosisSevere endVulnerabilitySymptomsTaskAssociation
2021
Medication strategies in first episode psychosis patients: A survey among psychiatrists
Kikkert M, Veling W, de Haan L, Begemann M, de Koning M, Sommer I, de Haan L, Veling W, van Os J, Smit F, Begemann M, Schuite‐Koops S, Marcelis M, Kikkert M, van Beveren N, Boonstra N, Rosema B, Bakker P, Gülöksüz S, Lokkerbol J, Brand B, Gangadin S, Geraets C, Hag E, Oomen P, Voppel A, van Amelsvoort T, Bak M, Been A, van den Bosch M, van den Brink T, Faber G, Grootens K, de Jonge M, Knegtering H, Kurkamp J, Mahabir A, Pijnenborg G, Staring T, Vaes W, Veen N, Veerman S, Wiersma S, Sommer I. Medication strategies in first episode psychosis patients: A survey among psychiatrists. Early Intervention In Psychiatry 2021, 16: 139-146. PMID: 33754470, PMCID: PMC9292219, DOI: 10.1111/eip.13138.Peer-Reviewed Original ResearchConceptsFirst psychotic episodeMedication discontinuationMedication strategiesPsychotic episodeFirst-episode psychosis patientsEpisode psychosis patientsSubstantial practice variationFirst-episode patientsMonths of remissionFirst-episode psychosisSpecific treatment strategiesSubsample of patientsPractice of cliniciansMaintenance therapyEarly discontinuationPsychosis patientsAntipsychotic drugsEpisode psychosisTreatment strategiesReduced dosePractice variationLong-term effectsSame doseDiscontinuationMost guidelines
2019
Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort)
Pandit R, Cianci D, Hark S, Rossum I, Ebdrup B, Broberg B, Garcia‐Portilla M, Bobes J, Vinkers C, Kahn R, Guloksuz S, Huitema A, Luykx J. Phenotypic factors associated with amisulpride‐induced weight gain in first‐episode psychosis patients (from the OPTiMiSE cohort). Acta Psychiatrica Scandinavica 2019, 140: 283-290. PMID: 31323113, PMCID: PMC6771865, DOI: 10.1111/acps.13074.Peer-Reviewed Original ResearchConceptsFirst-episode psychosis patientsPsychosis patientsWeight gainSchizophreniform disorderAntipsychotic-induced weight gainFirst-episode patientsManagement of schizophreniaLower baseline weightMultivariable regression modelsWeight-reducing strategiesOptimization of treatmentRegression modelsMajor depression disorderPhenotypic factorsAmisulpride treatmentBaseline weightEurope (Syst-Eur) trialMost antipsychoticsDepression disorderYoung subjectsBody weightPatientsBetter efficacyYounger ageAIWG
2016
Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications
Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-Induced Weight Gain in First-Episode Psychosis Patients: A Meta-Analysis of Differential Effects of Antipsychotic Medications. FOCUS The Journal Of Lifelong Learning In Psychiatry 2016, 14: 370-377. PMID: 31997958, PMCID: PMC6988756, DOI: 10.1176/appi.focus.140308.Peer-Reviewed Original Research